The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Delphine Loirat
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Nanobiotix; Novartis; Roche
 
Kevin Punie
Honoraria - Gilead Sciences (Inst); Lilly (Inst); Lilly (Inst); Mundipharma (Inst); Novartis (Inst); Novartis (Inst); Pfizer; Pfizer (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Lilly (Inst); Lilly (Inst); MSD (Inst); Novartis; Novartis; Novartis; Novartis (Inst); Novartis (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Teva (Inst); Vifor Pharma (Inst)
Research Funding - MSD (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; PharmaMar; Roche; Roche; Roche; Roche
 
Mafalda Oliveira
Honoraria - Eisai Europe; Guardant Health; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; ITeos Therapeutics; Pierre Fabre; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Pierre Fabre; Roche
 
Hope S. Rugo
Honoraria - Mylan; Puma Biotechnology; Samsung Bioepis
Consulting or Advisory Role - Napo Pharmaceuticals
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst)
 
Adam Brufsky
Consulting or Advisory Role - Abbvie; Agendia; Bayer; bioTheranostics; Coherus Biosciences; Coherus Biosciences; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; General Electric; Gilead Sciences; Immunomedics; Lilly; Merck; Michael J. Hennessy Associates; Myriad Pharmaceuticals; Novartis; Onc Live; Pfizer; Puma Biotechnology; Seagen; Tyme
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer
 
Kevin Kalinsky
Stock and Other Ownership Interests - Array BioPharma (I); GRAIL (I); Pfizer (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; bioTheranostics; Cyclacel; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; immunomedics; Ipsen; Lilly; Merck; mersana; Novartis; Oncosec; pfizer; Puma Biotechnology; Seagen
Speakers' Bureau - Lilly
Research Funding - Acetylon Pharmaceuticals (Inst); Amgen (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Zeno Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Pfizer
Other Relationship - Genentech; Immunomedics
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; GRAIL; Ipsen; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Veronique C Dieras
Honoraria - ABBVIE/ABBOTT; AstraZeneca; Daiichi Sankyo; Eisai Europe; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Seagen
Consulting or Advisory Role - ABBVIE/ABBOTT; AstraZeneca; Daiichi Sankyo Europe GmbH; Eisai Europe; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly; Novartis; Pfizer; Roche; Seagen
 
Lisa A. Carey
Research Funding - Abbvie (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Syndax (Inst); Veracyte (Inst)
Patents, Royalties, Other Intellectual Property - Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme. (I)
(OPTIONAL) Uncompensated Relationships - Aptitude Health (Inst); AstraZeneca/Daiichi Sankyo (Inst); Eisai; Exact Sciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Sanofi (Inst)
 
Luca Gianni
Consulting or Advisory Role - AMGEN; Artemida Pharma; AstraZeneca; BioMedical Insights; Celgene; Lilly; Menarini; Merck Sharp & Dohme; METIS Precision Medicine; Novartis; Pfizer; Revolution Medicines; Roche; Sanofi; Seagen; Synaffix; Zymeworks
Speakers' Bureau - Roche
Research Funding - Revolution Medicines (Inst); Zymeworks (Inst)
Patents, Royalties, Other Intellectual Property - Roche
Travel, Accommodations, Expenses - Celgene; Chugai Pharma; Pfizer; Roche
 
Martine J. Piccart-Gebhart
Consulting or Advisory Role - AstraZeneca; Camel-IDS; Frame Therapeutics; Immunomedics; Immutep; Lilly; Menarini; MSD; NBE Therapeutics; Novartis; Odonate Therapeutics; Pfizer; Roche/Genentech; Seagen; Seagen
Research Funding - AstraZeneca (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Menarini (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche/Genentech (Inst); Servier (Inst); Synthon (Inst)
Other Relationship - EU Cancer Mission Board; Oncolytics
 
Sibylle Loibl
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Medscape (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Puma Biotechnology (Inst); Roche (Inst); Seagen (Inst)
Speakers' Bureau - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Medscape (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Samsung (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)
 
Yanni Zhu
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
See-Chun Phan
Employment - Gilead Sciences
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche